Clinical and microbiological evaluation of temocillin for bloodstream infections with Enterobacterales: a Belgian single-centre retrospective study.
Journal
JAC-antimicrobial resistance
ISSN: 2632-1823
Titre abrégé: JAC Antimicrob Resist
Pays: England
ID NLM: 101765283
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
27
04
2022
accepted:
22
07
2022
entrez:
25
8
2022
pubmed:
26
8
2022
medline:
26
8
2022
Statut:
epublish
Résumé
Expanding the use of temocillin could be an important weapon in the fight against antimicrobial resistance. However, EUCAST defined clinical breakpoints for a limited number of species and only for urinary tract infections (UTI), including urosepsis but excluding severe sepsis and septic shock. Moreover, a dosage of 2 g q8h is advised in most cases. Evaluation of temocillin use for the treatment of bacteraemia, correlating clinical and microbiological outcomes with infection site, infection severity, temocillin dosage, Enterobacterales species and MIC. All adult patients with blood cultures positive for temocillin-susceptible Enterobacterales and treated with temocillin for ≥72 h from June 2018 until June 2021 were considered for inclusion. The primary outcome was clinical success, defined as resolution of infection signs, no relapse of the same infection and no antibiotic switch due to insufficient clinical improvement. The secondary outcome was microbiological success. In total, 182 episodes were included [140 UTI versus 42 non-UTI, 171 Temocillin 2 g q12h can be successfully used for the treatment of systemic UTI. Prospective studies are needed to assess outcomes and evaluate non-inferiority compared with other broad-spectrum antibiotics in non-UTI infections, including bacteraemia.
Sections du résumé
Background
UNASSIGNED
Expanding the use of temocillin could be an important weapon in the fight against antimicrobial resistance. However, EUCAST defined clinical breakpoints for a limited number of species and only for urinary tract infections (UTI), including urosepsis but excluding severe sepsis and septic shock. Moreover, a dosage of 2 g q8h is advised in most cases.
Objectives
UNASSIGNED
Evaluation of temocillin use for the treatment of bacteraemia, correlating clinical and microbiological outcomes with infection site, infection severity, temocillin dosage, Enterobacterales species and MIC.
Patients and methods
UNASSIGNED
All adult patients with blood cultures positive for temocillin-susceptible Enterobacterales and treated with temocillin for ≥72 h from June 2018 until June 2021 were considered for inclusion. The primary outcome was clinical success, defined as resolution of infection signs, no relapse of the same infection and no antibiotic switch due to insufficient clinical improvement. The secondary outcome was microbiological success.
Results
UNASSIGNED
In total, 182 episodes were included [140 UTI versus 42 non-UTI, 171
Conclusions
UNASSIGNED
Temocillin 2 g q12h can be successfully used for the treatment of systemic UTI. Prospective studies are needed to assess outcomes and evaluate non-inferiority compared with other broad-spectrum antibiotics in non-UTI infections, including bacteraemia.
Identifiants
pubmed: 36003075
doi: 10.1093/jacamr/dlac086
pii: dlac086
pmc: PMC9397121
doi:
Types de publication
Journal Article
Langues
eng
Pagination
dlac086Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
Références
Clin Microbiol Infect. 2015 Oct;21(10):899-905
pubmed: 26027916
Diagn Microbiol Infect Dis. 1984 Jan;2(1):55-63
pubmed: 6443203
Antimicrob Agents Chemother. 2022 Mar 15;66(3):e0205221
pubmed: 35099273
Antimicrob Agents Chemother. 1982 Sep;22(3):453-60
pubmed: 6982681
Clin Pharmacokinet. 2018 Mar;57(3):287-296
pubmed: 28849402
J Antimicrob Chemother. 2015 Mar;70(3):891-8
pubmed: 25433006
Int J Antimicrob Agents. 2018 Dec;52(6):762-770
pubmed: 30176355
Eur J Clin Microbiol Infect Dis. 2015 Aug;34(8):1693-9
pubmed: 25987247
J Antimicrob Chemother. 2008 Feb;61(2):382-8
pubmed: 18070831
JAC Antimicrob Resist. 2021 Feb 14;3(1):dlab005
pubmed: 34223083
J Antimicrob Chemother. 2021 Jun 18;76(7):1949-1950
pubmed: 33724352
J Antimicrob Chemother. 2021 Feb 11;76(3):784-788
pubmed: 33254232
Eur J Clin Microbiol. 1985 Feb;4(1):30-3
pubmed: 3872793
Am J Med. 1984 Feb;76(2):175-80
pubmed: 6695945
J Antimicrob Chemother. 2011 Nov;66(11):2628-31
pubmed: 21810837
Med Mal Infect. 2019 Feb;49(1):47-53
pubmed: 30396720
Eur J Clin Microbiol Infect Dis. 2021 Aug;40(8):1773-1777
pubmed: 33609262
Int J Antimicrob Agents. 2019 Dec;54(6):790-797
pubmed: 31284041
Diagn Microbiol Infect Dis. 2013 Feb;75(2):115-20
pubmed: 23290507
Crit Care. 2010;14(4):R126
pubmed: 20594297
PLoS One. 2021 Mar 10;16(3):e0248177
pubmed: 33690674
Antimicrob Agents Chemother. 1982 Oct;22(4):535-40
pubmed: 7181470
J Antimicrob Chemother. 2020 Dec 1;75(12):3652-3655
pubmed: 32814946
JAMA. 2016 Feb 23;315(8):775-87
pubmed: 26903336
GMS Infect Dis. 2021 Dec 21;9:Doc08
pubmed: 35106270
JAC Antimicrob Resist. 2021 Dec 28;4(1):dlab192
pubmed: 34988445